TCRR Logo.png
TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 06:45 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCRR Logo.png
TCR² Therapeutics to Present at the Truist Securities Life Sciences Summit
April 29, 2021 06:45 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
TCRR Logo.png
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting
April 10, 2021 08:31 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
TCRR Logo.png
TCR² Therapeutics to Present at the Needham Healthcare Conference
April 08, 2021 06:45 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
TCRR Logo.png
TCR² Therapeutics Establishes Commercial-Scale Cell Therapy Manufacturing Facility
March 29, 2021 08:00 ET | TCR2 Therapeutics
85,000 square foot state-of-the-art facility being built in Rockville, MarylandAccelerates TCR2’s commercial-scale manufacturing timelines with production anticipated in 2023Aaron Vernon hired as Vice...
TCRR Logo.png
TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 11, 2021 06:45 ET | TCR2 Therapeutics
-  Preliminary safety, efficacy and translational data from gavo-cel Phase 1 trial at AACR 2021 -  Preclinical data on autologous CD70 and allogeneic mesothelin TRuC data at AACR 2021 ...
TCRR Logo.png
TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline
March 10, 2021 16:45 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
TCRR Logo.png
TCR² Therapeutics to Participate in Two Upcoming Conferences in March
March 03, 2021 08:00 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
TCRR Logo.png
TCR² Therapeutics to Present at SVB Leerink Global Healthcare Conference
February 17, 2021 08:00 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
TCRR Logo.png
TCR² Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of Directors
February 04, 2021 08:00 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies...